title: Kasabach-Merritt phenomenon: a single centre experience.
abstract: OBJECTIVE
  Kasabach-Merritt phenomenon (KMP) can lead to life-threatening bleeding, and its optimum treatment has not been established. We review the experience of managing KMP in a single institution.
  
  
  METHODS
  A retrospective chart review on all children with KMP treated at the Hospital for Sick Children, Toronto, over an 18 yr period was carried out.
  
  
  RESULTS
  All 15 patients had profound thrombocytopenia and hypofibrinogenemia at presentation, half had bleeding symptoms, and three had cardiac failure. All patients received corticosteroids. Five responded to steroids alone, given for an average of 13 wk, increasing platelets to >20 x 10(9)/L at a mean of 6.2 d and fibrinogen >1 g/dL at 25.6 d. Ten patients received at least one other therapeutic modality in addition to steroids, including vincristine, interferon, anti-platelet agents and pentoxifylline. Five patients received vincristine, for a mean of 6 wk, with two patients responding. Eight patients received interferon, for a mean of 4 months, with two patients responding. Overall, the mean time to increasing platelets >20 x 10(9)/L was 56 d, to >150 x 10(9)/L was 88 d and fibrinogen >1 g/dL 49 d. Ten patients showed a partial response to embolisation, with a mean of 2.8 procedures performed. Thrombotic complications occurred in 7%. Twelve patients remain alive, with relapse in six patients, all treated successfully. One patient died, and two patients have been lost to follow-up.
  
  
  CONCLUSIONS
  KMP is a rare condition, with significant morbidity and mortality. The therapeutic approach should include a multidisciplinary team and consensus on guidelines.
authors.affiliation: Department of Haematology, Mercy University Hospital, Grenville Place, Cork, Ireland.
authors.forename: Clodagh
authors.initials: C
authors.lastname: Ryan
authors.forename: Vicotria
authors.initials: V
authors.lastname: Price
authors.forename: Philip
authors.initials: P
authors.lastname: John
authors.forename: Sanjay
authors.initials: S
authors.lastname: Mahant
authors.forename: Sylvain
authors.initials: S
authors.lastname: Baruchel
authors.forename: Leonardo
authors.initials: L
authors.lastname: Brandão
authors.forename: Victor
authors.initials: V
authors.lastname: Blanchette
authors.forename: Elena
authors.initials: E
authors.lastname: Pope
authors.forename: Miriam
authors.initials: M
authors.lastname: Weinstein
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007372:Interferons / Q000008:administration & dosage; D008297:Male; D010431:Pentoxifylline / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D010976:Platelet Count; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000305:Adrenal Cortex Hormones; D000972:Antineoplastic Agents, Phytogenic; D010975:Platelet Aggregation Inhibitors; D014750:Vincristine; D007372:Interferons; D010431:Pentoxifylline